RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Injection of synthetic polymer may improve facial wasting syndrome associated with HIV

Mar 20, 2006 - 5:00:00 AM
The patients' facial atrophy began to improve after the second injection and remained visibly improved through the end of the follow-up period (12 months). Twelve months after the end of the treatment period, the total thickness of skin and fat increased an average of 3.4 millimeters over the right cheek and 3.3 millimeters over the left cheek. More than half of the patients had rated their facial lipoatrophy as severe at the beginning of the study; after finishing treatment none did so, and 12 months later two patients (4 percent) rated their condition as severe and more than half rated it as absent to moderate. Fifteen (30 percent) of the participants experienced adverse reactions to the injections, but none were severe and none interrupted treatment because of them. Questionnaire results also revealed an improvement in self-perceptions of well-being after treatment.

 
[RxPG] Advances in treatments for HIV, including combination antiretroviral therapy, have enabled patients with the disease to live longer and healthier lives, according to background information in the article. Because of their longer lifespans, some patients with HIV are now experiencing additional complications. Changes in body fat distribution, including loss of subcutaneous fat in the face, may be a side effect of antiretroviral therapy and affect somewhere between 10 and 62 percent of individuals with HIV, the authors write. This facial lipoatrophy or facial wasting may lead to anxiety, depression, self-image problems and difficulties in social or sexual relationships.

Anna Maria Cattelan, M.D., University of Padua, Italy, and colleagues studied the efficacy, safety and tolerability of polylactic acid injections on 50 HIV¬–¬¬infected patients (42 men, 8 women) with moderate to severe facial lipoatrophy who visited an outpatient clinic between January and June 2002. Participants were given a full physical examination and questionnaire about the degree of their facial lipoatrophy and their overall health status when they enrolled in 2002. Facial photographs were taken and they underwent ultrasound evaluation, which recorded the thickness of the skin over their cheeks. The researchers then administered four sets of injections at the beginning of the study and again after 30, 45 and 60 days. The 16 patients with the most severe facial wasting received two additional injections after 75 and 90 days.

The patients' facial atrophy began to improve after the second injection and remained visibly improved through the end of the follow-up period (12 months). Twelve months after the end of the treatment period, the total thickness of skin and fat increased an average of 3.4 millimeters over the right cheek and 3.3 millimeters over the left cheek. More than half of the patients had rated their facial lipoatrophy as severe at the beginning of the study; after finishing treatment none did so, and 12 months later two patients (4 percent) rated their condition as severe and more than half rated it as absent to moderate. Fifteen (30 percent) of the participants experienced adverse reactions to the injections, but none were severe and none interrupted treatment because of them. Questionnaire results also revealed an improvement in self-perceptions of well-being after treatment.

The results of our study show that the correction of facial lipoatrophy with polylactic acid applications is safe and effective in increasing dermal thickness after a complete cycle of four to six injections, with a durability of response lasting until month 12 of follow-up, the authors conclude. These benefits were confirmed by ultrasonographic study, with a significant increase in dermal thickness that persisted at 36 to 40 weeks after the last injection. …Our patients did not need either hospitalization or chemoprophylaxis [preventive medications] and were treated using an outpatient regimen, without affecting their daily activity.




Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)